[PDF] Top 20 <p>Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients</p>
Has 10000 "<p>Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients</p>" found on our website. Below are the top 20 most common "<p>Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients</p>".
<p>Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients</p>
... the optic nerve. Two glaucoma specia- lists, who were masked to the study, were assigned to grade the vertical C/D ratio in the same eyes following anti-VEGF treatment using ... See full document
10
A Clinico-Pathological Study of the Structural and Functional Changes in the Retina and Optic Nerve Following Diabetic Retinopathy Treatments
... during anti-VEGF therapy, the macular thickness significantly decreased by 6 months and, while the patients were undergoing therapy, remained lowered over a 24 month time ...published ... See full document
299
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis
... in patients with center-involved DME, reported better visual and anatomical outcomes from baseline to 1 year with aflibercept, especially in patients with visual acuity ≤ 20/50 ...required ... See full document
8
<p>Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema</p>
... tory analysis of data from the RIDE/RISE trials, which demonstrated that ranibizumab reduced the risk of worsen- ing of DR severity, with improvement in DR severity seen in many ...Among patients who ... See full document
11
<p>Update in treatment of uveitic macular edema</p>
... 58. Radwan AE, Arcinue CA, Yang P, Artornsombudh P, Abu Al-Fadl EM, Foster CS. Bromfenac alone or with single intravitreal injection of beva- cizumab or triamcinolone acetonide for treatment of uveitic ... See full document
14
<p>Evaluation Of The Timing Of Intravitreal Bevacizumab Injection As Adjuvant Therapy To Panretinal Photocoagulation In Patients With Diabetic Macular Edema Secondary To Diabetic Retinopathy</p>
... examination. Macular OCT was performed using a Heidelberg Spectralis Machine (Heidelberg Engineering GmbH, Heidelberg, Germany), and it was per- formed before treatment and 1 month after IVB injection to assess ... See full document
6
Microperimetry and OCT angiography evaluation of patients with ischemic diabetic macular edema treated with monthly intravitreal bevacizumab: a pilot study
... All subjects presented with DRIL to some degree. The extent of DRIL was not affected by the treatment, and there was no correlation with final visual acuity. This could be due to our small sample size, as the literature ... See full document
7
<p>Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)</p>
... of patients with persistent or recurrent DME, the FAc implant led to positive long-term outcomes with acceptable tolerability and a reduced treat- ment ...in macular volume, which was reduced in 89% of ... See full document
10
<p>Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective</p>
... rst year and a mean duration between retreatment ...multicenter analysis of 79 eyes with DME treated with DEX implant and followed for at least 1 year after the fi rst injection,38 72% of eyes did not ... See full document
12
<p>Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study</p>
... Adult patients (aged ≥ 18 years) with type 1 or 2 diabetes mellitus who presented with clinically signi fi cant DME involving the center of the macula (de fi ned as the area of the center sub fi eld of optical ... See full document
10
An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema
... age-related macular degeneration but not for ...one year resulted in statistically significant improvement in visual acuity as measured by 10-letter gains (P= ... See full document
7
<p>Retinal angiographic alteration in diabetic macular edema after dexamethasone implantation: a case report</p>
... than anti-angiogenesis agent ther- apy to retard the macular edema in our ...than anti-angiogenesis agent ...least two months which might result from the anti-in fl ammatory ... See full document
7
Clinical study on the safety and efficacy of intravitreal triamcinolone for recalcitrant acular edema in south Indian population.
... to diabetic macular edema is ...or anti VEGF ...2006). Anti VEGF agents though a promising mode of therapy , remains a costly affair in a developing economy like ...India. ... See full document
86
<p>Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept</p>
... Consecutive patients with naïve DME underwent spectral domain optical coherence tomography (OCT) and fluorescein angiography (FA) of the midperiphery and were offered to have continuous injections of ... See full document
6
<p>Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study</p>
... statistical analysis was performed by using the pro- gramming language “ R ” (R Foundation for Statistical Computing, Vienna, ...the two years observation timepoint. Mean values between two different ... See full document
9
Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction
... of anti-vascular endothelial growth factor (anti-VEGF) now improve or stabilize visual acuity in a number of previously untreatable eye diseases, of which the main are age-related macular ... See full document
7
Intraocular pressure and ocular biometric parameters changes in migraine
... five patients during an attack showed an acute decrease in choroidal thickness from the values in the same patients during the attack- free period ... See full document
5
Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy: current status and future prospects
... Abstract: Diabetic retinopathy is a highly specific microvascular complication of diabetes and a leading cause of blindness ...peripheral nerve damage. All these changes lead to increased oxidative ... See full document
13
<p>Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema</p>
... In the present study, we demonstrated that the aqueous humour levels of IL-6, IL-8, eotaxin, G-CSF, IP-10, MCP- 1, and VEGF were signi fi cantly higher in eyes with DME than in control eyes with cataracts. IL-6 is ... See full document
8
The role of aflibercept in the management of diabetic macular edema
... Abstract: Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age ...proven treatments available for this condition, pharmacotherapy through the ... See full document
8
Related subjects